Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm's Nov. 16 filing addresses formatting issues that led to voluntary withdrawal earlier this month of initial NDA for the anti-epileptic and sets September 2006 PDUFA date.
You may also be interested in...
Eisai Epilepsy Drug Rufinamide Is "Approvable"
The company is seeking indications to treat Lennox-Gastaut syndrome and partial-onset seizures for the new molecular entity.
Eisai Epilepsy Drug Rufinamide Is "Approvable"
The company is seeking indications to treat Lennox-Gastaut syndrome and partial-onset seizures for the new molecular entity.
Astellas Will Give Cardiome Accelerated Milestone Payment For Atrial Fibrillation Drug
Revised agreement is a show of “confidence” following FDA’s refusal to file the original application for RSD1235.